Aequus Pharmaceuticals (AQSZF)

[BioSpecialist]

Great Management here / Massive undervalued ( Market cap $13.9 M) / New Deals regarding In and Outlicensing on the way . This undiscovered stock is a great buying opportunity with tremendous upside potential .GL

http://redirect.viglink.com/?key=bbb516d91daee20498798694a42dd559&u=http%3A//www.aequuspharma.ca/investors/press-release/aequus-provides-corporate-update-on-commercial-and-development-programs


Once-Weekly Transdermal Aripiprazole

Patch Positive Proof of Concept Clinical Data for Once-Weekly Transdermal Aripiprazole Patch: Aequus’ once-weekly transdermal aripiprazole program is being developed for the treatment of certain psychiatric disorders. In the first half of 2016, Aequus announced positive results from an initial Proof of Concept clinical study, which suggested the current formulation may provide sustained, seven-day delivery of therapeutic doses of aripiprazole. Aequus is preparing for the follow-on, multi-dose bioavailability study expected to be initiated in the second half of 2016. Aequus has also expanded the patent portfolio for this program, with a patent issued / allowed in five major countries or regions, including the US, Russia, Mexico, Japan and Australia, and pending in multiple additional territories. Aequus owns worldwide rights to the formulation described in the issued patent, and will look to partner commercial rights in markets outside of Canada as the program continues to advance.

Long-Acting Transdermal Anti-Nausea Patch

Advancement of IP and Formulation Optimization for Long-Acting Transdermal Anti-Nausea Patch: Aequus is advancing a once-daily and up to a once-weekly transdermal doxylamine and pyridoxine combination patch for the treatment of nausea and vomiting in pregnancy (NVP). During the first half of 2016, the Company completed preclinical studies and expects to advance the current formulation into Proof of Concept clinical studies in the second half of 2016. Aequus has filed an international patent that covers the current formulation and has ownership of worldwide rights.

Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring the maximum benefit is realized by shareholders.

---------------
Ian Ball – Former Global Head of Brand Maximization and Lifecycle Strategy with Novartis

?Strong relationships with key executives at Novartis and Sandoz
?Ability to structure low-upfront deals for valuable products